ABSTRACT
Immunopotentiating reconstituted influenza virosomes (IRIV) are spherical 150-nm sized particles consisting of a phospholipid bilayer in which influenza virus A/Singapore strain-derived hemagglutinin (HA) and neuraminidase (NA) are intercalated. As such, they resemble and mimic the influenza virus envelope. The difference from conventional liposome formulations lies in the inclusion of the viral envelope proteins HA and NA as well as viral phospholipids. Especially, the inclusion of influenza virus HA provides IRIV with delivery and immunogenic capacities. IRIV are licensed for human use as adjuvant in hepatitis A vaccination and as influenza subunit vaccine (1).
